Archiv: Randomised Evaluation of COVID-19 therapy (RECOVERY)


17.06.2020 - 09:18 [ Tagesschau ]

WHO zu britischer Corona-Studie: „Lebensrettender Durchbruch“

Bei dem Entzündungshemmer Dexamethason handle es sich um das erste Mittel, das die Sterblichkeit von Corona-Patienten verringere, die auf Sauerstoff oder Beatmungsgeräte angewiesen seien, sagte WHO-Chef Tedros Adhanom Ghebreyesus.

17.06.2020 - 09:15 [ WHO.int ]

WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients

Dexamethasone is a steroid that has been used since the 1960s to reduce inflammation in a range of conditions, including inflammatory disorders and certain cancers. It has been listed on the WHO Model List of Essential Medicines since 1977 in multiple formulations, and is currently off-patent and affordably available in most countries.

17.06.2020 - 09:11 [ Newsletter.co.uk ]

Dexamethasone: Coronavirus breakthrough as £5 steroid dexamethasone could have saved lives of 5,000 who died in UK claims Professor Martin Landray

The RECOVERY trial (which stands for ‘Randomised Evaluation of COVid-19 thERapY’) was funded by UKRI as part of the UKRI/DHSC/NIHR COVID-19 rapid research response.

The drug, which is currently used to treat ulcerative colitis, arthritis and some types of cancer, was found to have reduced the number of deaths of patients on ventilators and patients requiring oxygen by a third and by a fifth respectively.